Copyright
©The Author(s) 2019.
World J Gastroenterol. Jan 7, 2019; 25(1): 138-150
Published online Jan 7, 2019. doi: 10.3748/wjg.v25.i1.138
Published online Jan 7, 2019. doi: 10.3748/wjg.v25.i1.138
Table 1 Baseline circulating tumor cell characteristics of treatment-naïve patients with advanced pancreatic ductal adenocarcinoma according to circulating tumor cell status
Group | Patients n (%) |
Number of patients with no CTC | 23/107 (21.5) |
Number of patients with ≥ 1 CTC | 84/107 (78.5) |
Number of patients with ≥ 6 CTC | 55/107 (51.4) |
Number of patients with E-CTCs | 65/107(60.7) |
Number of patients with E/M-CTCs | 39/107 (36.4) |
Number of patients with M-CTCs | 49/107 (45.8) |
CTC dynamic range | |
Total CTC | 0-26 |
Median | 6 |
E-CTC | 1-11 |
E/M-CTC | 0-26 |
M-CTC | 0-9 |
Table 2 Correlation between total circulating tumor cell status and clinicopathological factors of patients with pancreatic cancer
Total CTC-negative patients (%) | Total CTC-positive patients (%) | P-value | |
Age, yr (median: 63, IQR: 52-76) | |||
< 60 | 8/23 (34.8) | 32/84 (38.1) | 0.769 |
≥ 60 | 15/23 (65.2) | 52/84 (61.9) | |
Gender | |||
Male | 16/23 (69.6) | 47/84 (56.0) | 0.313 |
Female | 7/23 (30.4) | 37/84 (44.0) | |
Ethnic group | |||
Han ethnic group | 14/23 (60.9) | 59/84 (70.2) | 0.346 |
Zhuang ethnic group | 5/23 (21.7) | 16/84 (19.1) | |
Li ethnic group | 4/23 (17.4) | 9/84 (10.7) | |
Differentiation | |||
Well | 3/23 (13.0) | 7/84 (8.3) | 0.435 |
Moderate | 13/23 (56.5) | 54/84 (64.3) | |
Poor | 7/23 (30.5) | 23/84 (27.4) | |
TNM stage | |||
I | 6/23 (26.1) | 4/84 (4.8) | < 0.001 |
II | 7/23 (30.4) | 13/84 (15.5) | |
III | 10/23 (43.5) | 39/84 (46.4) | |
IV | 0/23 (0) | 28/84 (33.3) | |
Lymph node metastasis | |||
Negative | 13/23 (56.5) | 34/84 (40.5) | 0.023 |
Positive | 10/23 (43.5) | 50/84 (59.5) | |
Neural invasion | |||
Negative | 10/23 (43.5) | 29/84 (34.5) | 0.247 |
Positive | 13/23 (56.5) | 55/84 (65.5) | |
Distant metastasis | |||
Negative | 23/23 (100) | 56/84 (66.7) | < 0.001 |
Positive | 0/23 (0) | 28/84 (33.3) |
Table 3 Univariate and multivariate Cox regression analyses of prognostic factors for overall survival in pancreatic cancer
Predictor | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P-value | HR | 95%CI | P-value | |
Age, < 60 vs ≥ 60 | 0.818 | 0.798-1.017 | 0.792 | |||
Gender (female vs male) | 0.928 | 0.781-1.130 | 0.952 | |||
Differentiation (well vs moderate vs poor) | 1.045 | 0.873-1.186 | 0.134 | |||
Ethnic group (Han/Zhuang/Li) | 0.917 | 0.834-1.048 | 0.866 | |||
TNM stage (I/II vs III/IV) | 1.452 | 1.215-1.475 | < 0.001 | 1.148 | 1.031-1.268 | 0.011 |
Lymph node metastasis (negative vs positive) | 1.287 | 1.048-1.364 | 0.007 | 1.198 | 1.036-1.380 | 0.017 |
Neural invasion (negative vs positive) | 1.008 | 0.781-1.155 | 0.949 | |||
Distant metastasis (negative vs positive) | 1.426 | 1.236-1.710 | < 0.001 | 1.521 | 1.256-1.887 | < 0.001 |
CTC, < 6 vs ≥ 6 | 1.849 | 1.717-2.238 | < 0.001 | 1.851 | 1.637-2.173 | < 0.001 |
Table 4 Correlation between total circulating tumor cell status and clinicopathological factors of patients with pancreatic cancer
Epithelia CTC (%) | Hybrid CTC (%) | Mesenchymal CTC (%) | ||||||||
Positive | Negative | P-value | Positive | Negative | P-value | Positive | Negative | P-value | ||
Age (yr) | < 60 | 24/65 | 16/42 | > 0.9 | 12/39 | 28/68 | 0.18 | 21/49 | 19/58 | 0.19 |
(36.9) | (38.1) | (30.8) | (41.2) | (42.9) | (32.8) | |||||
≥ 60 | 41/65 | 26/42 | 27/39 | 40/68 | 28/49 | 39/58 | ||||
(63.1) | (61.9) | (69.2) | (58.8) | (57.1) | (67.2) | |||||
Gender | Male | 37/65 | 26/42 | 0.56 | 24/39 | 39/68 | 0.56 | 28/49 | 35/58 | 0.77 |
(56.9) | (61.9) | (61.5) | (57.4) | (57.1) | (60.3) | |||||
Female | 28/65 | 16/42 | 15/39 | 29/68 | 21/49 | 23/58 | ||||
(43.1) | (38.1) | (38.5) | (42.6) | (42.9) | (39.7) | |||||
Differentiation | Well | 6/65 | 4/42 | 0.21 | 4/39 | 6/68 | 0.97 | 5/49 | 5/58 | 0.84 |
(9.2) | (9.5) | (10.3) | (8.8) | (8.1) | (9.3) | |||||
Moderate | 38/65 | 29/42 | 24/39 | 43/68 | 31/49 | 36/58 | ||||
(58.5) | (69.1) | (61.5) | (63.2) | (64.9) | (60.5) | |||||
Poor | 21/65 | 9/42 | 11/39 | 19/68 | 13/49 | 17/58 | ||||
(32.3) | (21.4) | (28.2) | (28) | (27) | (30.2) | |||||
TNM stage | I | 4/65 | 6/42 | 0.29 | 3/39 | 7/68 | 0.59 | 1/49 | 9/58 | < 0.01 |
(6.1) | (14.3) | (7.7) | (10.3) | (2) | (15.5) | |||||
II | 13/65 | 7/42 | 9/39 | 11/68 | 5/49 | 15/58 | ||||
(20) | (16.7) | (23.1) | (16.2) | (10.2) | (25.9) | |||||
III | 30/65 | 19/42 | 17/39 | 32/68 | 22/49 | 27/58 | ||||
(46.2) | (45.2) | (43.6) | (47.1) | (44.9) | (46.6) | |||||
IV | 18/65 | 10/42 | 10/39 | 18/68 | 21/49 | 7/58 | ||||
(27.7) | (23.8) | (25.6) | (26.4) | (42.9) | (12) | |||||
Lymph node metastasis | Negative | 25/65 | 22/42 | 0.08 | 18/39 | 29/68 | 0.78 | 24/49(49.0) | 23/58 | 0.26 |
(38.5) | (52.4) | (46.2) | (42.6) | (39.7) | ||||||
Positive | 40/65 | 20/42 | 21/39 | 39/68 | 25/49 | 35/58 | ||||
(61.5) | (47.6) | (53.8) | (57.4) | (51) | (60.3) | |||||
Neural invasion | Negative | 22/65 | 17/42 | 0.38 | 18/39 | 21/68 | 0.78 | 17/49 | 22/58 | 0.77 |
(33.8) | (40.5) | (46.2) | (42.6) | (34.7) | (37.9) | |||||
Positive | 43/65 | 25/42 | 21/39 | 39/68 | 32/49 | 36/58 | ||||
(66.2) | (59.5) | (53.8) | (57.4) | (65.3) | (62.1) | |||||
Distant metastasis | Negative | 46/65 | 33/42 | 0.25 | 27/39 | 52/68 | 0.26 | 25/49 | 54/58 | < 0.01 |
(70.8) | (78.6) | (69.2) | (76.5) | (51) | (93.1) | |||||
Positive | 19/65 | 9/42 | 12/39 | 16/68 | 24/49 | 4/58 | ||||
(29.2) | (21.4) | (30.8) | (23.5) | (49) | (6.9) | |||||
Ethnic group | Li ethnic group | 8/65 | 5/42 | 0.98 | 5/39 | 8/68 | 0.52 | 5/49 | 8/58 | 0.24 |
(12.3) | (11.9) | (12.8) | (11.8) | (10.2) | (13.8) | |||||
Han ethnic group | 44/65 | 29/42 | 25/39 | 48/68 | 32/49 | 41/58 | ||||
(67.7) | (69.1) | (64.1) | (70.6) | (65.3) | (70.7) | |||||
Zhuang ethnic group | 13/65 | 8/42 | 9/39 | 12/68 | 12/49 | 9/58 | ||||
(20) | (19) | (23.1) | (17.6) | (24.5) | (15.5) |
- Citation: Zhao XH, Wang ZR, Chen CL, Di L, Bi ZF, Li ZH, Liu YM. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice. World J Gastroenterol 2019; 25(1): 138-150
- URL: https://www.wjgnet.com/1007-9327/full/v25/i1/138.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i1.138